title: Effects of enfonidipine hydrochloride in dogs with experimental supraventricular tachyarrhythmia.
abstract: It is required not to increase the ventricular rate and to preserve the ventricular systolic function in treating supraventricular tachyarrhythmia (SVTA). The objective of this study is to investigate whether or not Efonidipine hydrochloride (EH), a T and L dual type Ca(2+) channel blocker, suppresses the increasing ventricular rate without reducing the ventricular systolic function using canine SVTA models by rapid atrial pacing (RAP) method. Clinically healthy fourteen beagles were used. The 14 dogs were randomly assigned to the EH-administered group (EH group, n=7) and non-EH-administered group (control group, n=7). The EH group was orally-administered EH at 5 mg/kg SID during RAP. On the other hand, the control group was applied RAP without oral administration of EH. Duration of RAP was for 3 weeks for both groups. The ventricular rate for the EH group was significantly lower than that for the control group. The left ventricular- fractional shortening for the control group declined significantly compared to baseline. Those for the EH group did not show any changes over time and were significantly higher than the control group. The ratio between pre-ejection period and ejection for the EH group were significantly lower than those of the control group. In conclusion, the study demonstrated that EH suppresses the increasing ventricular rate without reducing the ventricular systolic function in canine SVTA model. Therefore, EH is expected to become a new treatment for canine SVTA.
authors.affiliation: Laboratory of Veterinary Surgery, Tokyo University of Agriculture and Technology, Tokyo, Japan. shinndou@lake.ocn.ne.jp
authors.forename: Ryuji
authors.initials: R
authors.lastname: Fukushima
authors.forename: Ryou
authors.initials: R
authors.lastname: Tanaka
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Matsumoto
authors.forename: Noboru
authors.initials: N
authors.lastname: Machida
authors.forename: Hisashi
authors.initials: H
authors.lastname: Hirose
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Yamane
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Koyama
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009596:Nitrophenols / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D013599:Systole / Q000187:drug effects / Q000502:physiology; D013610:Tachycardia / Q000188:drug therapy / Q000662:veterinary*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy / Q000662:veterinary*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D009596:Nitrophenols; D009943:Organophosphorus Compounds; C066425:efonidipine